Biomarin Pharmaceutical (BMRN) EBT Margin (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly EBT Margin came in at 18.43% in Q1 2026, down 1352.0% YoY from 1.47% in Q1 2025, and up 693.57% on a QoQ basis from 3.1% in Q4 2025.
Biomarin Pharmaceutical (BMRN) EBT Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of EBT Margin data on file, last reported at 18.43% in Q1 2026.
- Quarterly EBT Margin fell 1352.0% year-over-year to 18.43% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.89% (down 1096.0% YoY) and the FY2025 annual result came in at 14.98%, down 401.0% from the prior year.
- EBT Margin improved to 18.43% in Q1 2026, from 3.1% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 36.09% in Q2 2025 to a low of 3.39% in Q3 2025.
- A 5-year average of 12.7% and a median of 11.9% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin soared 2106 bps — and 2025, when it sank 2580 bps.
- Tracing BMRN's EBT Margin over 5 years: stood at 3.27% in 2022, then surged by 192 bps to 2.99% in 2023, then surged by 659 bps to 22.7% in 2024, then slumped by 114 bps to 3.1% in 2025, then surged by 694 bps to 18.43% in 2026.
- The last three EBT Margin figures came in at 18.43% (Q1 2026), 3.1% (Q4 2025), and 3.39% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 6.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.20% |
| Mar 31, 2026 | 18.43% |
| Dec 31, 2025 | -3.10% |
| Sep 30, 2025 | -3.39% |
| Jun 30, 2025 | 36.09% |
| Mar 31, 2025 | 31.95% |
| Dec 31, 2024 | 22.70% |
| Sep 30, 2024 | 18.03% |
| Jun 30, 2024 | 18.56% |
| Mar 31, 2024 | 16.27% |
| Dec 31, 2023 | 2.99% |
| Sep 30, 2023 | 7.17% |
| Jun 30, 2023 | 11.90% |
| Mar 31, 2023 | 9.52% |
| Dec 31, 2022 | -3.27% |
| Sep 30, 2022 | -0.38% |
| Jun 30, 2022 | 6.53% |
| Mar 31, 2022 | 25.84% |
| Dec 31, 2021 | -14.80% |
| Sep 30, 2021 | -11.29% |